JP6407715B2 - 薬剤用量レジメンを経時的に最適化するためのシステム - Google Patents
薬剤用量レジメンを経時的に最適化するためのシステム Download PDFInfo
- Publication number
- JP6407715B2 JP6407715B2 JP2014508784A JP2014508784A JP6407715B2 JP 6407715 B2 JP6407715 B2 JP 6407715B2 JP 2014508784 A JP2014508784 A JP 2014508784A JP 2014508784 A JP2014508784 A JP 2014508784A JP 6407715 B2 JP6407715 B2 JP 6407715B2
- Authority
- JP
- Japan
- Prior art keywords
- blood glucose
- patient
- drug
- drug delivery
- cap
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000003814 drug Substances 0.000 title claims description 54
- 229940079593 drug Drugs 0.000 title claims description 50
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 88
- 239000008280 blood Substances 0.000 claims description 76
- 210000004369 blood Anatomy 0.000 claims description 76
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 72
- 239000008103 glucose Substances 0.000 claims description 72
- 238000012377 drug delivery Methods 0.000 claims description 62
- 102000004877 Insulin Human genes 0.000 claims description 44
- 108090001061 Insulin Proteins 0.000 claims description 44
- 229940125396 insulin Drugs 0.000 claims description 44
- 238000000034 method Methods 0.000 claims description 14
- 238000005259 measurement Methods 0.000 claims description 13
- 230000007246 mechanism Effects 0.000 claims description 13
- 238000001514 detection method Methods 0.000 claims description 8
- 230000008859 change Effects 0.000 claims description 7
- 238000009434 installation Methods 0.000 claims description 4
- 238000007599 discharging Methods 0.000 claims description 3
- 108010089308 Insulin Detemir Proteins 0.000 description 15
- 229940102988 levemir Drugs 0.000 description 15
- UGOZVNFCFYTPAZ-IOXYNQHNSA-N levemir Chemical compound CCCCCCCCCCCCCC(=O)NCCCC[C@@H](C(O)=O)NC(=O)[C@@H]1CCCN1C(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)CNC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=2N=CNC=2)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=2C=CC=CC=2)C(C)C)CSSC[C@@H]2NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)CSSC[C@H](NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC2=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H](CSSC1)C(=O)N[C@@H](CC(N)=O)C(O)=O)CC1=CC=C(O)C=C1 UGOZVNFCFYTPAZ-IOXYNQHNSA-N 0.000 description 15
- 230000006870 function Effects 0.000 description 13
- 238000004448 titration Methods 0.000 description 11
- 238000004422 calculation algorithm Methods 0.000 description 8
- 238000004891 communication Methods 0.000 description 6
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 3
- 238000003780 insertion Methods 0.000 description 3
- 230000037431 insertion Effects 0.000 description 3
- 229940127017 oral antidiabetic Drugs 0.000 description 3
- 108010092217 Long-Acting Insulin Proteins 0.000 description 2
- 102000016261 Long-Acting Insulin Human genes 0.000 description 2
- 229940100066 Long-acting insulin Drugs 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000021152 breakfast Nutrition 0.000 description 2
- 238000004364 calculation method Methods 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000002641 glycemic effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 238000005457 optimization Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- 102100025101 GATA-type zinc finger protein 1 Human genes 0.000 description 1
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 description 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 description 1
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000000806 elastomer Substances 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 230000014509 gene expression Effects 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000003538 oral antidiabetic agent Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 229920001690 polydopamine Polymers 0.000 description 1
- 230000000291 postprandial effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/24—Ampoule syringes, i.e. syringes with needle for use in combination with replaceable ampoules or carpules, e.g. automatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/145—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue
- A61B5/14532—Measuring characteristics of blood in vivo, e.g. gas concentration or pH-value ; Measuring characteristics of body fluids or tissues, e.g. interstitial fluid or cerebral tissue for measuring glucose, e.g. by tissue impedance measurement
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/14—Infusion devices, e.g. infusing by gravity; Blood infusion; Accessories therefor
- A61M5/168—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body
- A61M5/172—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic
- A61M5/1723—Means for controlling media flow to the body or for metering media to the body, e.g. drip meters, counters ; Monitoring media flow to the body electrical or electronic using feedback of body parameters, e.g. blood-sugar, pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/31568—Means keeping track of the total dose administered, e.g. since the cartridge was inserted
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/315—Pistons; Piston-rods; Guiding, blocking or restricting the movement of the rod or piston; Appliances on the rod for facilitating dosing ; Dosing mechanisms
- A61M5/31565—Administration mechanisms, i.e. constructional features, modes of administering a dose
- A61M5/31566—Means improving security or handling thereof
- A61M5/3157—Means providing feedback signals when administration is completed
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M5/32—Needles; Details of needles pertaining to their connection with syringe or hub; Accessories for bringing the needle into, or holding the needle on, the body; Devices for protection of needles
- A61M5/3202—Devices for protection of the needle before use, e.g. caps
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
- G16H10/60—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
- G16H10/65—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records stored on portable record carriers, e.g. on smartcards, RFID tags or CD
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
- G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
- G16H20/17—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients delivered via infusion or injection
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
- A61M5/31—Details
- A61M2005/3125—Details specific display means, e.g. to indicate dose setting
- A61M2005/3126—Specific display means related to dosing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/50—General characteristics of the apparatus with microprocessors or computers
- A61M2205/52—General characteristics of the apparatus with microprocessors or computers with memories providing a history of measured variating parameters of apparatus or patient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2205/00—General characteristics of the apparatus
- A61M2205/82—Internal energy supply devices
- A61M2205/8206—Internal energy supply devices battery-operated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M2230/00—Measuring parameters of the user
- A61M2230/20—Blood composition characteristics
- A61M2230/201—Glucose concentration
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Heart & Thoracic Surgery (AREA)
- Veterinary Medicine (AREA)
- Medical Informatics (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Surgery (AREA)
- Optics & Photonics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Diabetes (AREA)
- Infusion, Injection, And Reservoir Apparatuses (AREA)
- Tourism & Hospitality (AREA)
- Child & Adolescent Psychology (AREA)
- Economics (AREA)
- Human Resources & Organizations (AREA)
- Marketing (AREA)
- Strategic Management (AREA)
- General Physics & Mathematics (AREA)
- Theoretical Computer Science (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
Description
Claims (10)
- 患者の基本インスリン用量レジメンを経時的に最適化するためのシステムであって、
前記患者の血液サンプルを受承し、前記患者の血液サンプルの血糖値を測定し、測定した前記血糖値及び測定時間の情報を含む血糖データセットを生成するための血糖メータ(110、210);
患者作動型操作であって、インスリン含有薬剤の1用量の投与の指標である操作が実施されたことを検知する検知手段(250);
(a)複数の前記血糖データセット、(b)時間の関数として、検知された前記患者作動型操作を表すデータ、及び(c)初期の基本インスリン用量レジメンを表すデータ、を記憶するよう適合された、記憶手段;
前記記憶手段に作動可能に接続されたプロセッサ(240)であって、前記プロセッサは、前記患者の将来の血糖レベル測定値を所定の範囲内に維持するために、前記患者の現在のインスリン用量レジメンの構成要素を変化させるかどうか及びどの程度変化させるかを、複数の前記血糖データセットに基づいて決定するようプログラムされている、プロセッサ(240);並びに
前記患者のインスリン用量レジメンの構成要素を前記患者に伝達するための出力手段(260)
を備える、システムにおいて、
第2の所定の時間帯に前記患者作動型操作が検知されない場合、前記第2の所定の時間帯後の次の時間帯の第1の所定の時間帯に生成された所与の血糖データセットは、前記プロセッサによって無視される、
システム。 - (a)薬剤用リザーバ、
前記薬剤用流出口、及び
前記リザーバから薬剤を前記流出口を通じて吐出するための薬剤吐出機構を備える、薬剤送達デバイス(20);並びに
(b)前記薬剤送達デバイスに取り外し可能に設置でき、設置位置において前記流出口を覆うように適合されたキャップデバイス(10)であって、
(b1)前記血糖メータ、
(b2)前記記憶手段及び前記プロセッサ、
(b3)前記出力手段、並びに
(b4)前記検知手段
を備えるキャップデバイス(10)
を備える、薬剤送達アセンブリの形態のシステムであって、
前記検知手段は、前記キャップを少なくとも部分的に前記薬剤送達デバイスから所定の期間取り外した際にキャップ取り外しイベントを検知するよう適合され、前記キャップ取り外しイベントは前記インスリン含有薬剤の1用量の投与の指標である、請求項1に記載のシステム。 - (a)薬剤用リザーバ、
前記薬剤用流出口、及び
作動時に前記リザーバから所望の量の薬剤を前記流出口を通じて吐出するよう設定できる薬剤吐出機構、
1回分の吐出量を表す用量データを検出し、記憶し、転送する手段であって、前記吐出は前記インスリン含有薬剤の1用量の投与の指標である、手段
を備える、薬剤送達デバイス(502);並びに
(b)前記薬剤送達デバイスに取り外し可能に設置でき、設置位置において前記流出口を覆うように適合されたキャップデバイスであって、
(b1)前記血糖メータ、
(b2)前記記憶手段及び前記プロセッサ、
(b3)前記出力手段、並びに
(b4)前記検知手段
を備えるキャップデバイス
を備える、薬剤送達アセンブリの形態のシステムであって、
前記検知手段は前記薬剤送達デバイスから用量データを受信するよう適合される、請求項1に記載のシステム。 - (a)薬剤用リザーバ、
前記薬剤用流出口、
前記リザーバから薬剤を前記流出口を通じて吐出するための薬剤吐出機構、
前記血糖メータ、
前記記憶手段及び前記プロセッサ、
前記出力手段、並びに
前記検知手段
を備える、薬剤送達デバイスであって、
前記検知手段は前記薬剤吐出機構が作動したことを検知するよう適合され、前記吐出は前記インスリン含有薬剤の1用量の投与の指標である、薬剤送達デバイス;並びに
(b)前記薬剤送達デバイスに取り外し可能に設置でき、設置位置において前記流出口を覆うよう適合されたキャップデバイス
を備える薬剤送達アセンブリの形態の、請求項1に記載のシステム。 - 前記血糖データセットに含まれる血糖値が所定の範囲外の場合、前記プロセッサによって当該血糖データセットは無視される、請求項1〜4のいずれか1項に記載のシステム。
- 血糖メータ、検知手段、並びに、患者の将来の血糖レベル測定値を所定の範囲内に維持するために、前記患者のインスリン用量レジメンの構成要素を変化させるかどうか及びどの程度変化させるかを、血糖値に基づいて決定するよう構成されたプロセッサを備えるアセンブリを用いて、患者の基本インスリン用量レジメンを経時的に最適化するための方法であって、
前記血糖メータにおいて、血糖値を経時的に複数回測定するステップ;
前記血糖メータにおいて、測定した前記血糖値及び測定時間の情報を含む血糖データセットを生成するステップ;
前記検知手段において、患者作動型操作であって、インスリン含有薬剤の1用量の投与の指標である操作が実施されたことを検知するステップ;並びに
前記プロセッサにおいて、前記患者の将来の血糖レベル測定値を所定の範囲内に維持するために、前記患者の現在のインスリン用量レジメンの構成要素を変化させるかどうか及びどの程度変化させるかを、複数の前記血糖データセットに基づいて決定するステップ
を含み、
前記プロセッサにおいて、第2の所定の時間帯に前記患者作動型操作が検知されない場合、前記第2の所定の時間帯後の次の時間帯の第1の所定の時間帯に生成された所与の血糖データセットは、無視される、方法。 - 前記アセンブリが、薬剤送達デバイスを更に備える、請求項6に記載の方法。
- 前記患者作動型操作は、前記薬剤送達デバイスから薬剤の1用量を吐出させることである、請求項7に記載の方法。
- 前記薬剤送達デバイスは、薬剤吐出機構を有する主部、及び前記主部に取り外し可能に設置できるよう適合されたキャップを備え、
前記患者作動型操作は、前記キャップを少なくとも部分的に前記薬剤送達デバイスから所定の期間だけ取り外すことである、請求項7に記載の方法。 - 前記血糖メータは前記キャップ内に配設される、請求項9に記載の方法。
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11165063 | 2011-05-06 | ||
| EP11165063.6 | 2011-05-06 | ||
| US201161485291P | 2011-05-12 | 2011-05-12 | |
| US61/485,291 | 2011-05-12 | ||
| PCT/EP2012/058035 WO2012152628A1 (en) | 2011-05-06 | 2012-05-02 | System for optimizing a drug dosage regimen over time |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014514120A JP2014514120A (ja) | 2014-06-19 |
| JP6407715B2 true JP6407715B2 (ja) | 2018-10-17 |
Family
ID=44558231
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014508784A Active JP6407715B2 (ja) | 2011-05-06 | 2012-05-02 | 薬剤用量レジメンを経時的に最適化するためのシステム |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US9636461B2 (ja) |
| EP (1) | EP2705453B1 (ja) |
| JP (1) | JP6407715B2 (ja) |
| CN (1) | CN103782298A (ja) |
| WO (1) | WO2012152628A1 (ja) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104703644A (zh) * | 2014-01-13 | 2015-06-10 | 深圳市生活智能科技有限公司 | 药物注射信息监测结构及其系统、药物注射器 |
| US20150246179A1 (en) * | 2014-03-02 | 2015-09-03 | Nissim Zur | Device and method for drug dosing with administration monitoring, in particular for insulin pen integrated with smart phone apps. |
| JP6817074B2 (ja) | 2014-06-03 | 2021-01-20 | アムジエン・インコーポレーテツド | 制御可能な薬物送達システム及び使用方法 |
| US10593232B2 (en) * | 2014-08-19 | 2020-03-17 | Shl Medical Ag | Medicament injection device or injection mock-up demo device with motion detector to log and track user behaviour |
| US11164668B2 (en) * | 2014-10-23 | 2021-11-02 | Novo Nordisk A/S | Pen-type drug delivery device with electronic display on clip member |
| MX2017009484A (es) | 2015-01-23 | 2017-11-15 | Becton Dickinson Co | Método y dispositivo para capturar un evento de selección de dosis. |
| EP3132821B1 (en) | 2015-03-03 | 2018-12-19 | Innovative Precision Instruments Limited | Drug information detection apparatus and drug information detection type injection apparatus |
| EP3355970B1 (en) | 2015-09-30 | 2020-02-26 | Novo Nordisk A/S | Power efficinet add-on device |
| WO2017132577A1 (en) | 2016-01-29 | 2017-08-03 | Companion Medical, Inc. | Automatic medication delivery tracking |
| JP7064452B2 (ja) | 2016-06-30 | 2022-05-10 | ノボ・ノルデイスク・エー/エス | インスリン計画アドヒアランスデータの分析のためのシステムおよび方法 |
| WO2018001853A1 (en) * | 2016-06-30 | 2018-01-04 | Novo Nordisk A/S | Regimen adherence measure for insulin treatment based on glucose measurements and insulin pen data |
| MA45527A (fr) | 2016-06-30 | 2019-05-08 | Novo Nordisk As | Systèmes et procédés destinés à l'analyse des données d'adhérence de régime d'insuline |
| JP6756030B2 (ja) * | 2016-07-08 | 2020-09-16 | ノボ・ノルデイスク・エー/エス | 適応的目標グルコース値による基礎滴定 |
| KR20250057097A (ko) * | 2016-07-11 | 2025-04-28 | 에스에이치엘 메디컬 아게 | Rfid 태그 사용 가능한 바늘 차폐물 |
| US11752275B2 (en) | 2016-07-11 | 2023-09-12 | Shl Medical Ag | RFID tag enabled shield assembly |
| US9636464B1 (en) | 2016-08-01 | 2017-05-02 | Innovative Precision Instruments Limited | Drug delivery device and a drug information detection device |
| EP3868426A1 (en) * | 2016-12-08 | 2021-08-25 | Sanofi-Aventis Deutschland GmbH | Injection device |
| EP3554590A1 (en) * | 2016-12-13 | 2019-10-23 | Becton, Dickinson and Company | Event capture device for medication delivery instruments |
| USD853583S1 (en) | 2017-03-29 | 2019-07-09 | Becton, Dickinson And Company | Hand-held device housing |
| EP4290320B1 (en) | 2017-05-05 | 2025-12-24 | Ypsomed AG | Closed loop control of physiological glucose |
| US11197964B2 (en) | 2017-12-12 | 2021-12-14 | Bigfoot Biomedical, Inc. | Pen cap for medication injection pen having temperature sensor |
| US11077243B2 (en) | 2017-12-12 | 2021-08-03 | Bigfoot Biomedical, Inc. | Devices, systems, and methods for estimating active medication from injections |
| US11116899B2 (en) | 2017-12-12 | 2021-09-14 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems and devices |
| US11464459B2 (en) | 2017-12-12 | 2022-10-11 | Bigfoot Biomedical, Inc. | User interface for diabetes management systems including flash glucose monitor |
| US10987464B2 (en) | 2017-12-12 | 2021-04-27 | Bigfoot Biomedical, Inc. | Pen cap for insulin injection pens and associated methods and systems |
| US11083852B2 (en) | 2017-12-12 | 2021-08-10 | Bigfoot Biomedical, Inc. | Insulin injection assistance systems, methods, and devices |
| US11090439B2 (en) | 2017-12-12 | 2021-08-17 | Bigfoot Biomedical, Inc. | Therapy management systems, methods, and devices |
| EP3729446A1 (en) | 2017-12-21 | 2020-10-28 | Eli Lilly and Company | Closed loop control of physiological glucose |
| US20190328290A1 (en) * | 2018-04-27 | 2019-10-31 | Medtronic Minimed, Inc. | Glucose sensor-based tracking system |
| AU2019288473A1 (en) | 2018-06-22 | 2020-12-10 | Ypsomed Ag | Insulin and pramlintide delivery systems, methods, and devices |
| US12205699B1 (en) | 2018-10-30 | 2025-01-21 | Bigfoot Biomedical, Inc. | Method of pairing therapy devices using shared secrets, and related systems, methods and devices |
| WO2020120571A1 (en) * | 2018-12-14 | 2020-06-18 | Novo Nordisk A/S | Blod glucose data set optimization for improved hypoglycemia prediction based on machine learning implementation ingestion |
| US11948671B2 (en) | 2019-04-11 | 2024-04-02 | Medtronic Minimed, Inc. | Intelligent accessories for medicine dispensing device |
| CN110960758B (zh) * | 2019-12-10 | 2022-03-25 | 南通大学 | 全功能胰岛素注射器 |
| JP7702970B2 (ja) * | 2020-05-18 | 2025-07-04 | ベクトン ディキンソン フランス | Rfid(無線周波数識別)タグを備える医療用注入装置のためのカバー |
| KR102603796B1 (ko) * | 2021-08-20 | 2023-11-20 | 이석제 | 혈당측정이 가능한 스마트 인슐린 투입장치 |
| WO2023027250A1 (ko) * | 2021-08-23 | 2023-03-02 | 이석제 | 혈당측정이 가능한 스마트 인슐린 투입장치 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4731726A (en) | 1986-05-19 | 1988-03-15 | Healthware Corporation | Patient-operated glucose monitor and diabetes management system |
| CZ297361B6 (cs) | 1998-01-30 | 2006-11-15 | Novo Nordisk A/S | Injekcní stríkacka |
| US6192891B1 (en) * | 1999-04-26 | 2001-02-27 | Becton Dickinson And Company | Integrated system including medication delivery pen, blood monitoring device, and lancer |
| US6585698B1 (en) | 1999-11-01 | 2003-07-01 | Becton, Dickinson & Company | Electronic medical delivery pen having a multifunction actuator |
| GB0206792D0 (en) | 2002-03-22 | 2002-05-01 | Leuven K U Res & Dev | Normoglycemia |
| EP1391794A1 (en) | 2002-07-23 | 2004-02-25 | Novo Nordisk A/S | Device with time indicating means |
| DE60310233T2 (de) * | 2002-07-24 | 2007-09-13 | Deka Products Ltd. Partnership | Optischer verschiebungssensor für infusionsgeräte |
| US7404796B2 (en) * | 2004-03-01 | 2008-07-29 | Becton Dickinson And Company | System for determining insulin dose using carbohydrate to insulin ratio and insulin sensitivity factor |
| KR20060132434A (ko) * | 2003-11-06 | 2006-12-21 | 라이프스캔, 인코포레이티드 | 이벤트 통지 수단을 가지는 약물 전달 펜 |
| CN101125086A (zh) | 2006-08-18 | 2008-02-20 | 刘胜 | 闭环自动控制胰岛素注射系统 |
| DK2073871T3 (da) | 2006-09-29 | 2013-06-10 | Novo Nordisk As | Injektionsanordning med elektroniske detekteringsmidler |
| US8260558B2 (en) * | 2007-05-14 | 2012-09-04 | Abbott Diabetes Care Inc. | Method and apparatus for providing data processing and control in a medical communication system |
| US20090005726A1 (en) | 2007-06-27 | 2009-01-01 | Steven Paul Jones | Insulin Pump Having Expected Bolus Interval and an Early Bolus Interval |
| NO2260423T3 (ja) | 2008-04-04 | 2018-07-28 | ||
| JP2012507309A (ja) | 2008-07-18 | 2012-03-29 | ライフスキャン・インコーポレイテッド | 分析物測定及び管理装置並びに関連した方法 |
| WO2010098927A1 (en) | 2009-02-27 | 2010-09-02 | Lifescan, Inc. | Medical module for drug delivery pen |
| EP3865054A1 (en) | 2011-03-30 | 2021-08-18 | Novo Nordisk A/S | System for optimizing a patient s drug dosage regimen over time |
-
2012
- 2012-05-02 CN CN201280021833.5A patent/CN103782298A/zh not_active Withdrawn
- 2012-05-02 WO PCT/EP2012/058035 patent/WO2012152628A1/en not_active Ceased
- 2012-05-02 EP EP12719364.7A patent/EP2705453B1/en not_active Revoked
- 2012-05-02 US US14/115,799 patent/US9636461B2/en active Active
- 2012-05-02 JP JP2014508784A patent/JP6407715B2/ja active Active
-
2017
- 2017-03-21 US US15/464,968 patent/US10603437B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US20140200545A1 (en) | 2014-07-17 |
| EP2705453A1 (en) | 2014-03-12 |
| US10603437B2 (en) | 2020-03-31 |
| CN103782298A (zh) | 2014-05-07 |
| US9636461B2 (en) | 2017-05-02 |
| WO2012152628A1 (en) | 2012-11-15 |
| US20170189616A1 (en) | 2017-07-06 |
| JP2014514120A (ja) | 2014-06-19 |
| EP2705453B1 (en) | 2018-12-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6407715B2 (ja) | 薬剤用量レジメンを経時的に最適化するためのシステム | |
| JP6175049B2 (ja) | 患者の長期薬剤投与計画の最適化システム | |
| CN103874459B (zh) | 双用途咨询设备 | |
| CN103813821B (zh) | 用于随时间优化药物剂量方案的自适应系统 | |
| EP3174576B1 (en) | Continuous glucose monitoring injection device | |
| US10275573B2 (en) | User interface for diabetes management system | |
| ES2763940T3 (es) | Sistemas de gestión de administración de fármacos | |
| JP2015534666A (ja) | インスリンポンプおよびインスリンポンプの操作方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20150331 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20160115 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20160119 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20160418 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160615 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20161206 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170328 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20170405 |
|
| A912 | Re-examination (zenchi) completed and case transferred to appeal board |
Free format text: JAPANESE INTERMEDIATE CODE: A912 Effective date: 20170623 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180625 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180919 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6407715 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |